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Abstract
The treatment and outcomes for advanced prostate cancer have experienced signiﬁcant progress over recent years. Importantly, the additional beneﬁts of ‘up
front’ chemotherapy (docetaxel) and abiraterone, over and above conventional androgen deprivation, have been separately demonstrated in the multi-arm,
multi-stage (MAMS) STAMPEDE protocol, which continues recruitment to other questions. Alongside this, insights into the underlying molecular biology
and, inevitably, the molecular heterogeneity of prostate cancer are opening the door to new therapeutic approaches. Incorporating this understanding and
testing these hypotheses within STAMPEDE brings new challenges to the MAMS approach, but has the potential to further improve the outlook for this disease.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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This overview reﬂects the opinion and experience of the
authors and evidence has been presented accordingly. It is
based upon our own research ﬁndings and clinical trial
experience. It is not a systematic review.Introduction
The last decade has seen major advances in both the
understanding and the treatment of advanced prostate
cancer, with a number of agents gaining approval as stan-
dard of care (SOC) in castrate-resistant disease. More
recently, the additional beneﬁt of using these drugs earlier,
at ﬁrst presentation, has also been shown and is now
considered SOC [1e4]. In parallel, there has been signiﬁcant
progress in understanding prostate cancer biology thatAuthor for correspondence: C. Gilson, MRC Clinical Trials Unit at UCL,
Institute of Clinical Trials & Methodology, 90 High Holborn, 2nd Floor,
London, WC1V 6LJ, UK. Tel: þ44-20-7670-4943.
E-mail address: c.gilson@ucl.ac.uk (C. Gilson).
https://doi.org/10.1016/j.clon.2017.10.004
0936-6555/ 2017 The Royal College of Radiologists. Published by Elsevier Ltd. Th
org/licenses/by/4.0/).promises to further improve outcomes, but by nature
moves away from a ‘one size ﬁts all’ approach. Imple-
menting precision medicine requires the validation of pu-
tative predictive biomarkers within well-designed clinical
trials. Analysis of representative samples obtained as part of
a clinical trial protocol can support many stages of
biomarker discovery, assay development and qualiﬁcation,
as laid out in the Cancer Research UK Biomarker Roadmap
[5]. Knowledge gained through the genomic characterisa-
tion of advanced metastatic prostate cancer provides both
the rationale and the means to progress this research pri-
ority in the ﬁrst-line setting.
It has been shown that around 20% of metastatic
castrate-resistant prostate cancers (mCRPC) have loss-of-
function somatic genomic aberrations or germline de-
ﬁciencies in genes involved in DNA repair, in particular
those involved in the repair of double-stranded DNA breaks
using homologous recombination. The resulting homolo-
gous recombination deﬁciency (HRD) supports synthetic
lethality as a therapeutic approach in prostate cancer.
Importantly, the poly(ADP-ribose) polymerase (PARP) in-
hibitor, olaparib, has been shown to beneﬁt this group,is is an open access article under the CC BY license (http://creativecommons.
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[6,7].
However, the greatest absolute beneﬁt of effective ther-
apies may be observed when used early, at the initiation of
long-term androgen-deprivation therapy (ADT) [1e4].
Furthermore, prostate cancers exhibit signiﬁcant intra-
tumoural genetic heterogeneity, which increases in
advanced disease in response to multiple lines of therapy
[8,9]. Mechanistically, DNA repair-deﬁcient cancers can be
expected to acquire and tolerate somatic mutations at a
greater rate, which may thwart targeted precision medicine
approaches due to the increasing likelihood of acquired
secondary resistance and risk of sampling bias due to the
spatial genetic heterogeneity observed in metastatic pros-
tate cancer [10,11]. Together, this provides the rationale to
evaluate precision medicine approaches earlier, with the
aim of achieving the greatest impact on patient outcome.
Approval from Cancer Research UK and independent
scientiﬁc peer-review has been obtained to evaluate ruca-
parib within the STAMPEDE trial platform. Here we set out
the considerations and challenges faced when incorpo-
rating biomarker stratiﬁcation within an adaptive trial
platform, which will be the ﬁrst example of a biomarker-
directed treatment strategy in this disease setting.STAMPEDE
STAMPEDE (Systemic Therapy in Advancing or Metasta-
tic Prostate Cancer: Evaluation of Drug Efﬁcacy) is a well-
established randomised controlled trial that recruits men
with high-risk locally advanced or metastatic prostate
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Fig 1. Arms of the STAMPEDEtime, termed hormone-naive prostate cancer (HNPC) [12].
The trial uses a multi-arm multi-stage (MAMS) platform
design: multi-arm because many treatment approaches can
be tested simultaneously; multi-stage because pre-
speciﬁed interim analyses can be used to stop recruitment
early to arms showing insufﬁcient evidence of activity [13].
Data from all stages are included in the ﬁnal analysis of
efﬁcacy, powered on the primary outcome, overall survival.
The trial opened in 2005 with ﬁve ‘original comparisons’
evaluating the efﬁcacy of adding docetaxel, zoledronic acid
and celecoxib, given alone or in combination, to the then
SOC, ADT prostate radiotherapy. Since then a number of
new research arms have been added to undertake rando-
mised comparisons of: abiraterone; prostate radiotherapy
for patients with newly diagnosed metastatic disease
(M1jRT); enzalutamide given in combination with abir-
aterone; metformin, an anti-diabetic medication; and, most
recently, transdermal oestradiol, a proposed alternative
form of ADT (see Figure 1).Comparisons: Reported, Unreported and
Ongoing
The results of the ‘original comparisons’ and the ‘abir-
aterone comparison’ have been reported, with both doce-
taxel and abiraterone shown to signiﬁcantly improve
survival [2,3]. The addition of docetaxel improved median
survival from 71 months to 81 months; hazard ratio 0.78
(95% conﬁdence interval 0.66e0.93); P¼ 0.006. The
strength of evidence is most clearly apparent within the
metastatic subgroup where the beneﬁt is also reﬂected in
the results of the CHAARTED trial. Both trials contributed toLSOC+tE2
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C. Gilson et al. / Clinical Oncology 29 (2017) 778e786780the STOpCaP meta-analysis; aggregate data from 3206 pa-
tients with metastatic HNPC showed that docetaxel
improved 4 year survival by 9% (hazard ratio 0.77; 95%
conﬁdence interval 0.68e0.87; P< 0.0001) [14]. These data
have been practice changing [15]. The results of the ‘abir-
aterone comparison’ also show improved outcome; 3 year
survival improved from 76% to 83%; hazard ratio 0.63 (95%
conﬁdence interval 0.52e0.76) [3]. Opportunistic data ac-
quired through the overlapping randomised population
accrued between 2011 and 2014 were presented at ESMO
2017 and suggest superior progression-free survival with
abiraterone but a comparable survival outcome [16]. The
‘M1jRT comparison’ and ‘enzalutamide and abiraterone
comparison’ continue in follow-up, with survival results
expected in the next 1e3 years. Recruitment is ongoing to
two comparisons evaluating metformin and transdermal
oestradiol as re-purposed anti-cancer therapies, both pro-
posed to mitigate the adverse cardiovascular and metabolic
effects of long-term androgen suppression [17,18]. STAM-
PEDE is investigating whether adding metformin to the
current SOC for non-diabetic men can improve all-cause
survival, and whether transdermal oestradiol, shown to
offer superior cardiovascular, quality-of-life and bone
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Fig 2. Future STAMPEDE randomisation schema.
Table 1
Considerations for biomarker-enriched trial designs
Framework for incorporating biomarker stratiﬁcation
in a platform trial
1. Can the biomarker of interest be reliably measured
using a validated assay?Rationale to Incorporate Biomarker
Selection within STAMPEDE
The ‘rucaparib comparison’ will be embedded into
STAMPEDE by way of a protocol amendment as the most
efﬁcient route to address this question in this disease
setting (see Figure 2). Through further adaptation, we avoid
establishing a competing biomarker-selected trial within an
overlapping population, which could risk impacting on
accrual and potentially generalisability of results through
depletion of biomarker-deﬁned groups hypothesised to
have both prognostic and predictive effects. Through
incorporation we can determine and control the impact on
the ongoing comparisons and continue to answer impor-
tant research questions for both biomarker-positive and
-negative patients through an inclusive trial platform. This
is key to sustaining efﬁcient accrual to all comparisons and
conducting cost-effective evaluation of new agents, partic-
ularly for those targeted at low-frequency biomarkers.2. What is test-performance in clinically available
samples representative of the population of interest?
3. Is the biomarker prognostic necessitating a separate control
in order to distinguish a prognostic from a predictive effect?
4. What is the biomarker prevalence in the population
of interest?
5. What is the strength of evidence of a predictive effect,
i.e. the speciﬁcity of the biomarker?
6. What is the strength of evidence to support the rationale
and clinical efﬁcacy of the targeted therapy in the
biomarker-deﬁned group?
7. What is the overlap between this biomarker-deﬁned
group and others of interest?
8. What are the implications for other overlapping
accruing comparisons?Biomarker Stratiﬁcation: Considerations
When planning biomarker-enriched clinical trials
requiring prospective biomarker characterisation there are
several aspects that require consideration to inform the trial
design and feasibility of implementation (summarised in
Table 1).
Biomarker Measurement
The reliable identiﬁcation of the biomarker-positive
population of interest requires an analytically validatedassay shown to perform to an acceptable standard in
clinically available samples [22]. In the case of the STAM-
PEDE trial population, these are typically small, prostate
core biopsies stored as formalin-ﬁxed, parafﬁn-embedded
tumour blocks. Preliminary data have highlighted the
C. Gilson et al. / Clinical Oncology 29 (2017) 778e786 781impact of pre-analytical variables such as variation be-
tween sites’ ﬁxation protocols in the ability to extract
sufﬁciently high-quality DNA required for analysis. This
has been recognised by others; Genomic England have
reported that the quality of routinely obtained cancer
samples may often be suboptimal for molecular analysis
and are leading several initiatives aiming to improve
sample quality and inform the most suitable methods for
sample collection and storage [23]. The clinical utility of
the method of biomarker measurement should be assessed
in representative clinical samples to estimate the test-
failure rate. This in turn informs the numbers needed to
screen, a crucial parameter in deﬁning the cost, accrual
time and, therefore, feasibility of implementation. The
impact of a high test failure rate is greatest when aiming to
evaluate low-prevalence biomarkers when this can render
a trial infeasible.
To be workable within a clinical trial screening window
the biomarker assessment must be available within a
reasonable timeframe. Several factors will affect turn-
around around times, including pathology department
resources, shipping distances, the capacity of the
biomarker provider and the need to batch for cost-
efﬁciency. The risk of a long turnaround time is that
randomisation and, therefore, treatment, is delayed. The
effect of this will probably be greatest in trials recruiting
patients with progressive disease where a participant’s
clinical status may change, making them ineligible during
the time taken to complete screening. However, in all
disease settings, the time required to undertake
biomarker analysis should not risk disadvantaging pa-
tients’ access to treatment. In trial platforms where mul-
tiple randomisations are possible, biomarker analysis
should be completed in such time that patients remain
eligible for all possible randomisations. This is relevant for
STAMPEDE, which will continue to randomise to non-
biomarker selected comparisons.
Prognostic Importance
Aberrations in BRCA and other HRD genes are negatively
prognostic in prostate cancer and, therefore, patients allo-
cated to the research arm of the ‘rucaparib comparison’ will
only be evaluated against comparable biomarker-positive
controls [24e27]. Evidence of a prognostic effect can
inform the design of biomarker-enriched trials and affect
the assessment of feasibility, particularly of low-frequency
biomarkers. When considering a biomarker-selected ran-
domisation within a platform trial, knowledge of a prog-
nostic effect informs whether it is justiﬁable to share a
control arm, with resulting efﬁciencies (namely fewer
control arm patients). If the biomarker is known to be
prognostic, separate comparisons are required in order to
distinguish a predictive from a prognostic effect, as exem-
pliﬁed by the design of FOCUS-4 [28]. Knowledge of a
prognostic effect can also inform the size of a trial powered
to detect a difference in time-to-event outcomes. If the
survival time is shorter, the information required for reli-
able analyses (e.g. number of deaths for a trial powered onthe primary outcome of survival) will be accrued sooner
and, therefore, a smaller trial may be required.
However, the acquisition of robust prognostic informa-
tion for emerging biomarker-deﬁned groups can be chal-
lenging. Retrospective retrieval of archival samples is
vulnerable to bias, with the risk that those patients who
have subsequently progressed and enrolled onmCPRC trials
requiring archival tissue analysis are under-represented.
Additionally, it has been suggested that the quality of the
DNA extracted from formalin-ﬁxed parafﬁn-embedded
samples declines with sample age; this has been sup-
ported by the experience of the STAMPEDE group to date. It
is hoped that through data sharing, for example through
contribution to genetic consortia, it will be possible to
inform clinical trial design and target research efforts in
poor prognostic genetic subpopulations, aiming to improve
outcome in those patients with the greatest unmet clinical
need.
Biomarker Prevalence
The duration of recruitment to the ‘rucaparib compari-
son’ will depend on the frequency of DNA repair defects in
men eligible for STAMPEDE. Evidence from mCRPC cohorts
and primary localised prostate cancer has that shown DNA
repair defects are more common in metastatic disease
[8,29e32]. Around 20% of mCRPC cohorts (range 7e27%)
have detectable mutations in one or more of 14 genes
involved in homologous recombination, including BRCA1,
BRCA2, ATM, BARD1, CHEK2, PALB2, RAD51 [6,7,9,33e40].
The vast majority of the prostate cancer cohorts proﬁled to
date have either consisted of men with advanced, heavily
pre-treated CRPC or localised prostate cancer suitable for
radical prostatectomy. Therefore, knowledge of the genomic
landscape of men presenting with high-risk locally
advanced or metastatic prostate cancer (i.e. eligible for
STAMPEDE) is currently very limited. Furthermore, all
sequenced mCRPC series to date involve patients partici-
pating in trials, precision medicine initiatives or autopsy
programmes at tertiary academic centres and are, therefore,
vulnerable to selection bias (see Table 2) [6,7,9,34,36,37].
Eligibility to the ‘rucaparib comparison’ will be limited to
metastatic HNPC with a detectable pathogenic mutation in
one or more of 14 HRD-related genes and the trial design
has been developed based on an estimated biomarker
prevalence of 10e15%. A feasibility assessment is planned 1
year after the activation of recruitment; accumulating
prevalence data acquired in the screened populationwill be
reviewed and adjustments to the target screening accrual
numbers made accordingly.
The frequency of the biomarker of interest in the target
population is crucial in developing the best approach to
therapeutic evaluation within a biomarker-enriched trial.
Trials restricting enrolment to low-prevalent biomarker
groups risk being very costly, given the numbers needed to
screen; additionally, the high screen failure rates can deter
patients and investigators, negatively impacting on accrual.
This contributes to the rationale for incorporating both
biomarker-selected and -unselected randomisations within
Table 2
DNA repair deﬁciency in prostate cancer: summary of prevalence data
Ref Cohort details M0 (n) M1 (n) % BRCAm % HRD*
[30] HNPC suitable for prostatectomy 112 - 1% 4%
[31] Low/intermediate risk HNPC 333 - 4% 13%
[29] Mixed HNPC 55 2 0% 11%
[32] Mixed cohort, predominantly M0 181 37 0 0
[8] Mixed cohort, both HNPC and mCRPC 25 20 12% 20%
[29] Mixed, fatal mCRPC sampled at rapid
autopsy and HNPC suitable for
prostatectomy
11 50 2% 7%
[34] Selected due to unusual clinical course,






[36] Fatal mCPRC sampled at rapid autopsy 54 7% 16%
[6] mCRPC trial participants at academic centres - 150 14% 23%
[7] mCRPC in an unselected PARPi trial - 50 14% 27%
[37] Cohorts participating in clinical trials, rapid
autopsy programmes or precision medicine
initiatives at academic centres
692 6.2% (gBRCA) 11.2% (gHRD)
[35] Sporadic mCRPC eligible for abiraterone +/-
PARPi
- 80 25%
[33] Sporadic mCRPC eligible for PROREPAIR-B
(prospective cohort study)
- 419 4.2% (gBRCA) 9.1% (gHRD)
BRCAm ¼ BRCA mutant, CNA ¼ copy number alteration, gBRCA ¼ germline BRCA mutation, gHRD ¼ germline HRD mutation, HNPC ¼
hormone-naïve prostate cancer, M0 ¼ non-metastatic prostate cancer, M1 ¼ metastatic prostate cancer, tNGS ¼ targeted next generation
sequencing, mCRPC ¼ metastatic castrate resistant prostate cancer, PARPi ¼ PARP inhibitor, WES ¼ whole exome sequencing.
*Homologous recombination deﬁciency deﬁned as pathogenic aberration in one or more: BRCA1, BRCA2, ATM, BARD1, BRIP, CDK12,
CHEK2, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L.
C. Gilson et al. / Clinical Oncology 29 (2017) 778e786782one trial platform, in order to sustain accrual to low-
prevalence biomarker groups.
Evidence of a Predictive Effect
Eligibility for the ‘rucaparib comparison’ will be
restricted to the biomarker-positive population based on
the evidence of a predictive effect demonstrated for PARP
inhibition in mCRPC. Justiﬁcation of biomarker enrichment
requires evaluating the strength of evidence of a predictive
effect; this also informs the effect size [41]. In the scenario
that the evidence of a predictive effect is judged insufﬁcient
to limit treatment to only biomarker-positive patients, it
may be preferable to enrol an unselected population and,
through prospective biomarker assessment, stratify by
biomarker status to enable pre-planned subgroup analyses.
If, however, there is good evidence of a predictive effect,
such that enrichment can be justiﬁed, randomisation may
be limited to the biomarker population. One approach to
the challenge of deﬁning the level of evidence required is to
adopt a pragmatic approach: would randomisation of an
unselected population be acceptable and, therefore,
feasible? Here, evaluation within an adaptive MAMS trial
platform is advantageous as it is possible to initially ran-
domise the population with the strongest evidence of a
predictive effect and then subsequently activate random-
isation in a broader group should sufﬁcient activity be
shown. Early stopping rules could be used in this scenario,
but the value of being able to test the speciﬁcity of the
marker is high: it may be that the research treatment couldoffer a broader beneﬁt, which risks being missed if an
enrichment design is adopted and not subsequently
evaluated.
The magnitude of the targeted treatment effect is also
dependent on the evidence of a predictive effect; where
there is strong evidence of a predictive effect in a
biomarker-deﬁned group, the treatment effect may be
expected to be greater than for a non-targeted therapy in
an unselected population. The vast majority of data
demonstrating the efﬁcacy of PARP inhibition have been
acquired in the setting of ovarian or breast cancer and the
strongest evidence of a predictive effect has been shown
for inactivating mutations in BRCA1 and BRCA2 [42e45].
Preliminary evidence of an anti-tumour effect has been
shown for mCRPC, with defects in several homologous
recombination genes, including BRCA2, ATM and CHEK2
[7]. However, as ATM and CHEK2 mutations have not been
described in other BRCA-associated cancers to date, here
the evidence of a predictive effect is judged to be less,
limited to prostate cancer and pre-clinical data [7,40]. A
balance is required in order to evaluate the treatment in
the broadest patient group hypothesised to beneﬁt, while
accepting that where there is less evidence of a predictive
effect, it may be appropriate to target a smaller treatment
effect, thus requiring a larger randomised population. It
should be considered whether to include a pre-planned
subgroup analysis in the group(s) with the strongest evi-
dence of a predictive effect; a step-down approach to
analysis may be taken, as shown by other PARP trials
[44,46].
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Only through pairing the biomarker-deﬁned population
with an effective therapeutic strategy can precision medi-
cine approaches improve outcome. However, biomarker-
treatment pairings may fail to translate to patient beneﬁt
due to an incomplete understanding of the biology of the
biomarker or the interaction between the biomarker and
the therapy [47]. Metastatic prostate cancer has been
shown to be associated with multiple genetic aberrations,
but in order to realise the therapeutic potential of this, it is
necessary to distinguish mutations of signiﬁcance. Ulti-
mately, the highest level of evidence supporting an identi-
ﬁed genetic alteration as an oncogenic driver and, therefore,
a valuable therapeutic target, requires prospective evalua-
tion within a clinical trial, including demonstration that
biomarker-negative cohorts do not beneﬁt from the tar-
geted therapy [48]. Such evidence needs to be tumour site-
speciﬁc due to the concept of epistasis, the geneegene in-
teractions proposed to explain the observed attenuated
biological consequences of speciﬁc genetic aberrations ac-
cording to tumour type. Examples of this include the
differing impact of a BRAF V600E mutation, predictive of
sensitivity to vemurafenib in melanoma and dabrafenib in
non-small cell lung cancer, but not in the context of colo-
rectal cancer. The latter is proposed to be due to the feed-
back of epidermal growth factor receptor, thus emphasising
that driver classiﬁcation requires contextual knowledge of
other mutations present [49,50].
One of the most well-described and seemingly per-
plexing challenges to the implementation of precision
medicine approaches is intratumoural heterogeneity [51].
This can be considered as either spatial, the variation be-
tween different sites of disease, or temporal, the variation
at different time points, for example pre- and post-
treatment [52]. The key challenge to implementing preci-
sion medicine in metastatic prostate cancer is spatial
heterogeneity, as this has the potential to introduce sam-
pling bias [51]. Evidence from multi-regional sampling of
cases of mCRPC obtained at rapid autopsy and sequential
sampling shows metastatic spread to be polyclonal and
polyphyletic, with evidence of metastatic-to-metastatic
spread and both spatial and temporal heterogeneity [10].
This provides a powerful rationale to evaluate precision
approaches in the ﬁrst-line treatment of metastatic HNPC
at the point closest to the sampling of the primary tumour.
However, evidence of spatial heterogeneity will continue
to motivate the investigation of alternative approaches to
biomarker assessment, such as circulating tumour DNA.
Such approaches are particularly relevant to this disease
setting, given the predominance of bone metastatic
involvement, which remains challenging to sample
adequately to allow genetic analyses [53].Overlapping Biomarkers of Interest
In order for a trial platform such as STAMPEDE to eval-
uate multiple biomarkeretherapeutic pairings, knowledgeof the overlap between predictive biomarkers is required.
This requires systematic proﬁling of a representative pop-
ulation; ongoing work being conducted as part of STAM-
PEDE aims to inform this. Genomic characterisation of
clinical trial cohorts has been invaluable in other disease
settings, such as those conducted as part of the S-CORT
programme associated with FOCUS-4, which have informed
biomarker prevalence, prognostic impact and overlap
[54,55]. If, for example, all cases of HRD prostate cancers
overlap with a second biomarker of interest, then the
feasibility of accruing to both comparisons would be
dependent on the prevalence of both biomarkers or
expanding accrual internationally. Greater understanding of
the genetic proﬁle of high-risk or metastatic prostate cancer
will be crucial in identifying and designing future potential
comparisons to be assessed in STAMPEDE.What Next for STAMPEDE?
In preparation for activating randomisation to the
‘rucaparib comparison’, a biomarker-screening pilot will
start in late 2017. This will aim to establish the necessary
processes to obtain rapid, prospective sequencing data prior
to randomisation in order to determine eligibility.
Following the pilot phase, biomarker screening will be
activated in all participating centres when randomisation
opens in early 2018. The development of this, the ﬁrst
biomarker-selected comparison, has highlighted the
requirement for preliminary biomarker-focused research to
inform the implementation of such approaches. The
STAMPEDE protocol has included participant consent for
the collection and analysis of archived tumour samples. As
more outcome data become available there are a growing
number of opportunities to support biomarker develop-
ment through correlative analysis. Funded by Prostate
Cancer UK, the STRATOSPHere consortium (STratiﬁcation
for RAtional Treatment-Oncomarker pairings of STAMPEDE
Patients starting long-term Hormone treatment) aims to
undertake a co-ordinated, multi-centre approach to gener-
ating preliminary data to accelerate the introduction of
biomarker-selected comparisons with STAMPEDE.
One such future comparison in development aims to
evaluate the addition of a checkpoint inhibitor in men with
metastatic HNPC. Recognising that there are currently
insufﬁcient data to support the use of a predictive
biomarker-enrichment strategy, an alternative approach to
biomarker development is suggested. As part of the
STRATOSPHere consortium, a parallel translational pro-
gramme would aim to prospectively collect and character-
ise the randomised population. Then, if supported by
external data, prospective enrichment may subsequently be
implemented as part of the multi-stage design. Alterna-
tively, it may be possible to power a subgroup analysis by
biomarker status, based on the prevalence data acquired.
Finally, in order to accelerate biomarker validation it will be
important to establish the necessary infrastructure that al-
lows clinical and molecular characterisation and endorses
data sharing.
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The management of men with high-risk prostate cancer
has lagged behind other tumour types where molecular
characteristics routinely inform therapeutic choice.
Knowledge gained from the genomic characterisation of
CRPC cohorts, together with the evidence of the therapeutic
relevance of DNA repair defects, provides the rationale to
investigate a precision approach to treatment. Through
further adaptation, STAMPEDE will evaluate the addition of
a PARP inhibitor in this, the disease setting in which the
greatest impact of outcome has been shown to date. The
implementation of precision medicine approaches in low-
frequency biomarker groups is challenging, but incorpo-
rating both biomarker-selected and -unselected random-
isations within a single platform offers further efﬁciencies
to the MAMS approach and ensures that the trial platform
remains inclusive and attractive to patients, investigators
and funders. Correlative translational analyses using
STAMPEDE data offer unparalleled opportunity for
biomarker development, which can continue to inform the
trial design and generate the required preliminary data as
laid out in the framework presented in this review. Through
this latest adaption, we aim to ensure STAMPEDE remains
innovative and continues to accelerate the acquisition of
knowledge that will improve outcomes for men affected by
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